methyl 1-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 1-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate
• 英文别名: Methyl 1-[[(Trifluoromethyl)sulfonyl]oxy]-2-naphthoate；methyl 1-(trifluoromethylsulfonyloxy)naphthalene-2-carboxylate
• 化学式: C₁₃H₉F₃O₅S
• 分子量: 334.273
• InChiKey: JCIUYBDKEDCBKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 1-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate 在 manganese(IV) oxide 、 copper(l) iodide 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢气 、 四丁基碘化铵 、 三乙胺 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 乙酸乙酯 、 1,2-二氯乙烷 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 112.0h， 生成 2-(4-methoxyphenyl)-3-tosyl-1,2,3,4-tetrahydrobenzo[f]isoquinoline
  参考文献：
  名称：

  Concise Route to 3-Arylisoquinoline Skeleton by Lewis Acid Catalyzed C(sp³)–H Bond Functionalization and Its Application to Formal Synthesis of (±)-Tetrahydropalmatine

  摘要：

  An expeditious route to furnish an isoquinoline skeleton via hydride shift mediated C-H bond functionalization was developed. In this process, an unusual [1,5]-H shift without the assistance of the adjacent heteroatom took place to produce tetrahydroisoquinoline derivatives in good to excellent chemical yields. The formal synthesis of (+/-)-tetrahydropalmatine was achieved by exploiting this new transformation.

  DOI：

  10.1021/ol300180w
• 作为产物：
  描述：

  1-羟基-2-萘甲酸 在 硫酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 30.0h， 生成 methyl 1-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate
  参考文献：
  名称：

  通过酰基膦的脱羰作用差异取代的膦

  摘要：

  通过一种具有“预连接和转化”过程的方法，开发了一种新的膦路线，该过程通过可容易地由羧酸和二取代的膦制备的酰基膦中间体进行。使用镍催化剂对这些酰基膦进行有效的脱羰，可得到相应的膦。该方法表明，羧基可起到类似于卤化物或三氟甲磺酸酯的作用，以将取代的磷原子引入芳环。

  DOI：

  10.1021/acs.orglett.7b00579

文献信息

• Palladium-Catalyzed C–P(III) Bond Formation by Coupling ArBr/ArOTf with Acylphosphines
  作者：Xingyu Chen、Hongyu Wu、Rongrong Yu、Hong Zhu、Zhiqian Wang

  DOI：10.1021/acs.joc.1c00937

  日期：2021.7.2

  differential phosphination reagents is reported. The acylphosphines show practicable reactivity with ArBr and ArOTf as the phosphination reagents, though they are inert to the air and moisture. The reaction affords trivalent phosphines directly in good yields with a broad substrate scope and functional group tolerance. This reaction discloses the acylphosphines’ capability as new phosphorus sources for the direct

  据报道，钯催化的 ArBr/ArOTf 的 C-P 键形成反应使用酰基膦作为差异膦化试剂。酰基膦显示出与作为膦化试剂的 ArBr 和 ArOTf 的实际反应性，尽管它们对空气和湿气呈惰性。该反应直接以良好的收率提供三价膦，具有广泛的底物范围和官能团耐受性。该反应揭示了酰基膦作为直接合成三价膦的新磷源的能力。
• Facile Photochemical Synthesis of 1,1?-Binaphthyls
  作者：Pablo Wessig、Gunnar Müller

  DOI：10.1071/ch08141

  日期：——

  The photochemical synthesis of highly functionalized 1,1′-binaphthyls 9 by photodehydro-Diels–Alder reaction of esters 8 is reported. It was found that π-stacking interactions between a naphthyl moiety already present in the reactants 8 and an aryl group tethered in the propargyl position of these esters clearly influence the regio- and diastereoselectivity of the reaction. The formation of undesired

  报道了通过酯 8 的光脱氢-Diels-Alder 反应光化学合成高度官能化的 1,1'-联萘 9。发现已经存在于反应物8中的萘基部分与束缚在这些酯的炔丙基位置上的芳基之间的π-堆积相互作用明显影响反应的区域选择性和非对映选择性。可以通过在萘基部分的 2 位引入封闭甲氧基来抑制不希望的菲 10 的形成。在一种情况下，实现了 32:68 的非对映异构体比率。这是通过光脱氢-Diels-Alder 反应选择性合成联芳基化合物的第一个例子。
• [EN] N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 CONTENANT DES LACTAMES LIÉS À N
  申请人：MERCK SHARP & DOHME

  公开号：WO2012158475A1

  公开（公告）日：2012-11-22

  The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一般式（I）的N-连接内酰胺化合物，这些化合物是M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包括这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• [EN] M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 ET PROCÉDÉS POUR LES UTILISER
  申请人：MERCK SHARP & DOHME

  公开号：WO2017160670A1

  公开（公告）日：2017-09-21

  The present invention is directed to compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, or pharmaceutically acceptable salts thereof, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一般式(I)的化合物或其药用盐，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物或其药用盐的药物组合物，以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。
• [EN] BENZOISOQUINOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE BENZOISOQUINOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2018005249A1

  公开（公告）日：2018-01-04

  The present invention is directed to substituted benzoisoquinolinone compounds, their salts, pharmaceutical compositions comprising them and their use in therapy. In particular, the invention is directed substituted benzoisoquinolinone compounds which are muscarinic M1 receptor positive allosteric modulators. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M1 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M1 receptors are involved.

  本发明涉及替代苯并异喹啉酮化合物、它们的盐、包含它们的药物组合物以及它们在治疗中的用途。具体来说，该发明涉及替代苯并异喹啉酮化合物，这些化合物是肌胆碱M1受体阳性变构调节剂。本发明还涉及所述化合物在潜在治疗或预防M1受体参与的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗M1受体参与的疾病中的用途。